NeuroBo Pharmaceuticals, Inc. (NRBO)
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.
It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.
The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001.
NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
545 Concord Avenue, Suite 210
Cambridge, Massachusetts 02138
|Fiscal Year||January - December|
|Dr. Ben Gil Price M.D.||Chief Executive Officer and Pres|
|Dr. Matthew Bardin BCPS, Pharm.D.||Senior Vice President of Operations|
|Frank Kondrad||Vice President of Corporate and Business Development|
Latest SEC Filings
|Nov 13, 2023||10-Q||Quarterly Report|
|Nov 13, 2023||8-K||Current Report|
|Nov 6, 2023||8-K||Current Report|
|Oct 30, 2023||8-K||Current Report|
|Sep 22, 2023||8-K||Current Report|
|Sep 19, 2023||8-K||Current Report|
|Sep 15, 2023||8-K||Current Report|
|Aug 24, 2023||8-K||Current Report|
|Aug 14, 2023||8-K||Current Report|
|Aug 9, 2023||10-Q||Quarterly Report|